Skip to main content

Table 2 Utility Scores by BCVA Level

From: Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective

BCVA level

BSE utility

WSE utility

86–100

0.85

0.85

76–85

0.76

0.84

66–75

0.69

0.82

56–65

0.61

0.81

46–55

0.54

0.79

36–45

0.46

0.78

26–35

0.39

0.75

 < 25

0.35

0.75

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us